Overview
- Novo trimmed full-year guidance for the fourth time, now targeting revenue growth of up to 11% and operating profit growth of up to 7% at constant exchange rates.
- Third-quarter profit fell to DKK 23.7 billion with sales below expectations, marking the slowest growth since early 2021 before Wegovy’s U.S. launch.
- The company is eliminating roughly 11% of roles, about 9,000 jobs worldwide including 5,000 in Denmark, with restructuring charges totaling about DKK 8 billion.
- Eli Lilly’s stronger GLP-1 sales and upgraded outlook intensified pressure on Novo, whose shares are down about 50% this year after an intraday drop of as much as 4.8% and partial rebound.
- Novo raised its offer for Metsera to as much as $10 billion, a bid the startup’s board preferred, while Pfizer countered at $8.1 billion and continues to challenge the process in court.